Goudswaard, Lucy J.
Smith, Madeleine L.
Hughes, David A.
Taylor, Roy
Lean, Michael
Sattar, Naveed
Welsh, Paul
McConnachie, Alex
Blazeby, Jane M.
Rogers, Chris A.
Suhre, Karsten
Zaghlool, Shaza B.
Hers, Ingeborg
Timpson, Nicholas J.
Corbin, Laura J.
Funding for this research was provided by:
British Heart Foundation (AA/18/1/34219, RE/18/6/34217)
University of Bristol Academic Career Development Fund
Wellcome Trust (218495/Z/19/Z, WT 217065/Z/19/Z, 202802/Z/16/Z)
Diabetes UK (17/0005645)
Medical Research Council
University of Bristol NIHR Biomedical Research Centre (BRC-1215-2001)
Cancer Research UK (C18281/A29019)
National Institute of Health and Care Research (NIHR) Health Technology Assessment Programme (HTA 09/127/53)
Article History
Received: 11 July 2023
Accepted: 8 November 2023
First Online: 29 November 2023
Competing interests
: RT has received lecture honoraria from Eli Lilly, Nestle Health and Janssen. NS has received consulting and/or speaker honoraria from Abbott Laboratories, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Janssen, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Roche Diagnostics, and Sanofi; and grant funding support paid to his University from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche Diagnostics outside the submitted work. All other authors declare no competing interests.